Simulated Environment Concepts, Inc. is unique in its offering of SpaCapsule®, the only device on the market that addresses both body and mind issues, which are the most frequent complaint of the working public. Stress and musculoskeletal problems are the most commonly reported factors associated with work related illness. These are both major issues, accounting for untold physical and emotional anguish, affecting work performance and satisfaction as well as personal relationships.

Stress alone is believed to affect nearly 20 million Americans, with stress levels having increased substantially in children, teenagers, and the elderly. A simple Google search on the word “stress” reveals the overwhelming size of the market for stress related treatments.

This, of course, opens up a tremendous market opportunity for anyone offering an effective tool for stress and body therapy, which is just what SpaCapsule represents. Doctors’ offices, clinics,

Nutra Pharma has announced their intention to begin the registration for their over-the-counter pain reliever in both Canada and Europe. Currently, the company is marketing a similar product, Cobroxin, within the United States. Cobroxin is used for the treatment of moderate to severe (Stage 2) chronic pain.

According to the North American Chronic Pain Association of Canada, it is estimated that 18% of Canadians suffer from severe chronic pain. Additionally, the Pain in Europe report, which is the largest European survey of chronic pain sufferers, reports that chronic pain effects one in five adults across Europe.

Dr. Paul Redi, CEO of ReceptoPharm, stated, “We have already started in-depth conversations with regulatory specialists with the intent to begin the registration of our over-the-counter pain reliever in Canada and Europe. We are confident that our pain reliever can be successfully registered in the near term based on the existing regulatory requirements in those

Nutra Pharma Corp.

(Public, OTC:NPHC)

Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The

On July 24, New York-based biopharmaceutical company Regeneron Pharmaceuticals Inc. (REGN) announced that its once-weekly injection Arcalyst (Rilonacept) received a positive response from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA). The drug is used for treating Cryopyrin-Associated Periodic Syndromes (CAPS), a group of rare, inherited, auto-inflammatory conditions characterized by life-long, recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain, and fatigue.

CHMP has recommended that rilonacept, an interleukin-1 blocker, be granted marketing authorization under exceptional circumstances. Such authorizations are granted to products on which comprehensive data cannot be provided by the company, which may happen due to the the rarity of the condition. The agency also asked Regeneron to  provide new information, if available, pertaining to the drug every year for review.

The company submitted a Marketing Authorization Application (MAA) with the EMEA for Arcalyst for the treatment of CAPS in the European